Market Cap
₹8,678 Cr.
P/E
0.00
Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max

Company Timeline

Forensics

10 Yes

Positive for this company

2 Neutral

Neutral for this company

5 No

Negative for this company

0 No Data

Insufficient data to analyse

ROE
Latest
-9.16%
3yr Average
-6.33%
5yr Average
-1.06%
Net Profit Margin
Latest
-5.49%
3yr Average
-4.13%
5yr Average
0.77%
ROCE
Latest
8.2%
3yr Average
5.45%
5yr Average
6.23%
Debt to Equity
Latest
1.25
3yr Average
1.07
5yr Average
1.04
Market Share
50% (as of Mar 19)
Acarbose - Market Share
21% (as of Mar 19)
Acetazolamide - Market Share
11% (as of Mar 19)
Amlodipine - Market Share
18% (as of Mar 19)
Benzonatate - Market Share
52% (as of Mar 19)
Buspirone - Market Share
36% (as of Mar 19)
Calcitriol SGC - Market Share
20% (as of Mar 19)
Efavirenz - Market Share
27% (as of Mar 19)
Ibuprofen Rx - Market Share
23% (as of Mar 19)
Ketoconazole - Market Share
63% (as of Mar 19)
Methoxsalen - Market Share
65% (as of Mar 19)
Ranitidine - Market Share
53% (as of Mar 19)
Vanco Caps - Market Share
Show more
Revenue mix

Product Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Customer Segment

locked
Source
|
Latest
|
locked
Historic

Operating Profit Break-Up

locked
Source
|
Latest
|
locked
Historic

Asset Break-Up - Segment Wise

locked
Source
|
Latest
|
locked
Historic

Asset Break-Up

locked
Source
|
Latest
|
locked
Historic
Show more
Operational Metrics

    Select a Metric
    • Number of ANDA's Filed in USA (.)
    • Number of ANDA's Approved By USFDA (.)
    • R&D as a % of Total Sales (%)
    Peer Comparison
    Brands
    Pediacare
    Suppliers
    Company Filing
    Show Previous Years
    Discussions & Analysis